What is Laurus Labs' plan for the new Pharma Zone?

Laurus Labs has secured 532 acres of land in India to establish a ₹5,630 crore ($680 million) Laurus Pharma Zone (LPZ) for manufacturing pharmaceutical products, with plans to create 6,350 jobs over the next eight years.

Which major Indian pharma companies are recalling drugs in the US?

Sun Pharma, Lupin, and Dr Reddy's Laboratories are recalling various drug products in the US market due to manufacturing issues and product mix-ups, according to the US FDA.

How has Genpharmasec expanded its business?

Genpharmasec has acquired a 70% stake in Derren Healthcare for ₹34.15 crore ($4.1 million), allowing the company to expand its activities and enter the formulations manufacturing segment.

Home / Business and Economy / Laurus Labs Inks $5.6B Deal for Massive Pharma Manufacturing Zone

Laurus Labs Inks $5.6B Deal for Massive Pharma Manufacturing Zone

28 Jul

•

Summary

Laurus Labs secures 532-acre land for new pharma manufacturing hub
Sun Pharma, Lupin, and Dr Reddy's recall drugs in US due to quality issues
Genpharmasec acquires 70% stake in Derren Healthcare for $34M

Laurus Labs Inks $5.6B Deal for Massive Pharma Manufacturing Zone

In a major expansion move, Laurus Labs has announced that the Andhra Pradesh government has allotted 531.77 acres of land to the company to set up a new Laurus Pharma Zone (LPZ) for manufacturing pharmaceutical products. The company plans to invest ₹5,630 crore ($680 million) and create 6,350 jobs in three phases over the next eight years. This land acquisition secures a critical component for Laurus Labs' future growth.

Elsewhere in the Indian pharma industry, leading drugmakers Sun Pharma, Lupin, and Dr Reddy's Laboratories are recalling various products in the US market due to manufacturing issues and product mix-ups. The US FDA has reported these recalls, which are a setback for the companies as they work to maintain quality standards in their global operations.

In a separate development, Genpharmasec has acquired a 70% stake in Derren Healthcare for ₹34.15 crore ($4.1 million). This strategic move will allow Genpharmasec to expand its activities and enter the formulations manufacturing segment.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.